Merck Presents Results of Study
Merck said a study of its once-daily formulation of ISENTRESS (raltegravir) for the treatment of adults with HIV-1 infection found that after 48 weeks of treatment, 1200 mg raltegravir was statistically non-inferior to the marketed formulation approved dose of ISENTRESS 400 mg twice-daily. Furthermore, the study showed comparable rates of[Read More…]